Celgene's Phase II psoriatic arthritis trial meets primary endpoint.
In: PharmaWatch: Biotechnology, Jg. 8 (2009-08-01), Heft 8, S. 7-7
report
Zugriff:
The article reports on the positive preliminary findings gathered by biopharmaceutical company Celgene Corp. on its Phase II trial of apremilast, an orally available small molecule for psoriatic arthritis, in the U.S. Celgene reveals that its Phase II, three-arm study of apremilast had met its primary target of assessment of ACR20 at 12 weeks. The results has posted the significant improvement on the efficacy and safety of apremilast towards patients with psoriatic arthritis.
Titel: |
Celgene's Phase II psoriatic arthritis trial meets primary endpoint.
|
---|---|
Zeitschrift: | PharmaWatch: Biotechnology, Jg. 8 (2009-08-01), Heft 8, S. 7-7 |
Veröffentlichung: | 2009 |
Medientyp: | report |
Schlagwort: |
|
Sonstiges: |
|